Good read I found on Stockhideout
PharmaCyteBiotech-logo.png
Biotech plays are in hot demand on Wall Street for a simple reason: these companies are where the top brains are solving big money diseases.
I’m talking massive medical opportunities like cancer ($100B) and diabetes ($245B), chances to build a pharma empire from the ground up.
Along the way, of course, there are plenty of shots at quicker glory . . . which is exactly where PMCB comes leaping back onto my screen.
As you recall from its last bull run for us, PMCB has taken a potential CURE FOR DIABETES through its first pre-clinical trial. (Read more)
That’s incredibly ambitious for any 0.15 start-up, but in the here and now I want you to look at the technical situation forming on PMCB:
PMCB-sho.png
The tight channel PMCB has explored in the last couple weeks has created a platform for the next move . . . reminiscent of back in March, right before the PPS lifted off on a 3-digit bull run.
Of course it takes a signal for any market rocket to blast. That’s where the biotech buzz comes to the table. As you recall, the skeleton key to PMCB’s technology is putting “good” cells in a tiny box where they can go into the body and release tumor-killing drugs right where they’re needed.
Find the right cells and in theory PMCB can cure cancer, repair a sick diabetic pancreas, you name it. They already proved in the lab that the cell boxes work, and that pre-clinical trial shows that they’re safe to implant in living animals.
One tiny demonstration of how important this technology might be: PMCB has official FDA “orphan” status to try its boxes out on pancreatic cancer. The average orphan drug that makes it through the process is worth $1B . . . no surprise big pharma execs are happy to get a piece of the action.
And no wonder the analysts are jumping all over each other to assign some brain-meltingly high targets on what PMCB may actually be worth. That one I linked to tells a 4-digit story!
Analyst coverage? Extreme price targets? FDA perks? Big pharma talent crowding the board? It looks to me like PMCB has a lot of the puzzle pieces to become one of those gigantic biotech companies you read about in Barrons.
But unlike those companies, PMCB is still available in 0.01 increments instead of multiple Benjamins per share. But talk about ground floor rising! Remember, every tiptoe toward the clinic unlocks value.
The clock is ticking. The base has been established. It’s time to see PMCB strut its stuff!
Sincerely,
StockHideOut
